Replies to post #203924 on Biotech Values

[stuartscott8900]

dew

regarding RVNC.the stock is down from mid 30's to 14 in a year, and insiders have not stepped up to plate to purchase any stock and the insiders for the most part hold very little stock.Does that cause any concern for you?

[Bickema]

That is the goal. Even a small royalty on sales of Botox in certain indications could be worth a lot to RVNC.

if this turns out to be true then this would be a major oversight by Allergan considering Revance paid only $2 million upfront.

Seems wishful thinking to think Allergan could make such a mistake after dominating the Botulinum Toxin market for so long, one must think they have been well aware of these patents for some time and had no inclination to purchase them no?